CrownPeak Helps Pharmaceutical/Biotech Client CV Therapeutics

LOS ANGELES, CA. (May 06, 2008) – CrownPeak, the company defining the future of content management, today announced that CV Therapeutics, Inc. has implemented CrownPeak’s award-winning content management system (CMS) to manage three of the company’s web sites. CV Therapeutics, a biopharmaceutical company primarily focused on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases, represents CrownPeak’s first client in the pharmaceutical or biotech industry.
The CrownPeak CMS has enabled internal stakeholders at CV Therapeutics to update general company, R&D, investor and career information on the corporate web site www.cvt.com. The CMS is also being utilized to manage information on www.Ranexa.com for the company’s premiere product Ranexa┬« (ranolazine extended-release tablets), the first new pharmaceutical approach to treat chronic angina in the United States in more than 20 years.
“Being able to communicate accurate information with our various stakeholders in a timely fashion is absolutely critical in our industry,” says Tina Sampath, Associate Director of eMarketing for CV Therapeutics. “Prior to implementing the CrownPeak CMS, we were completely reliant upon a third party web agency. Now with CrownPeak, we have complete control of the update process for our websites.
In addition to implementing the actual content management system, CrownPeak manages web hosting and web analytics for CV Therapeutics.
“With the understanding that timely dissemination of accurate information is very importance in their field, our aim was to tailor the control of each web site to match the goal of their particular audience,” says Jim Howard, chief executive officer of CrownPeak. “We are honored that a distinguished pharmaceutical firm such as CV Therapeutics would entrust the entire management of their content systems to us. We look forward to building out new features that will continue to make it easier for CV Therapeutics to communicate with their various audiences.”

Source: CrownPeak

Tags: